Category: 54856-23-4

Chen, Hong-hua published the artcileEfficacy of manual reduction combined with betahistine mesylate in treatment of benign paroxysmal positional vertigo, SDS of cas: 54856-23-4, the publication is Xiandai Zhenduan Yu Zhiliao (2017), 28(7), 1235-1236, database is CAplus.

To explore the efficacy of manual reduction combined with drugs in the treatment of 60 cases of benign paroxysmal positional vertigo. Patients who were diagnosed with benign paroxysmal positional vertigo in our hospital from Feb. 2013 to Jan. 2015 were collected and randomly divided into a study group and a control group. The basic treatment of the two groups was manual reduction, and the study group was treated with betahistine mesylate tablets. The therapeutic effects of the two groups were compared for benign paroxysmal positional vertigo. The two groups were scored by the Vertigo Disorder Rating Scale before and after treatment. The therapeutic effects of the study group and the control group for benign paroxysmal positional vertigo were 100% and 66.7%, resp., and there was a difference (P < 0.05). The study group and the control group had no difference in the scores of the Vertigo Disorder Rating Scale before treatment (P > 0.05). There was a difference in the scores of the vertigo disorder rating scale between the study group and the control group after treatment (P < 0.05). This article believes that manual reduction combined with drugs has a definite effect in the treatment of benign paroxysmal positional vertigo and can significantly improve the symptoms of patients.

Xiandai Zhenduan Yu Zhiliao published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, SDS of cas: 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Yang, Wan-jing published the artcileEffect of vestibular rehabilitation training combined with betahistine mesylate on elderly patients with benign paroxysmal positional vertigo, Category: pyridine-derivatives, the publication is Huanan Guofang Yixue Zazhi (2016), 30(1), 71-72, database is CAplus.

Objective To investigate the effect of vestibular rehabilitation training combined with betahistine mesylate on elderly patients with benign positional paroxysmal vertigo (BPPV). Methods 120 elderly patients with BPPV were randomized into three groups: group A was treated with vestibular rehabilitation training, group B was treated by oral administration of betahistine mesylate, and group C was treated by vestibular rehabilitation training combined with oral administration of betahistine mesylate. Results The total effective rate of group C was significantly higher than that of group A and group B (χ²=11.61, P<0.05), and the total effective rate of group B was significantly higher than that of group A (χ²=8.90, P<0.05). The incidence of adverse reactions of group C was significantly lower than that of group A and group B (χ²=4.50, P<0.05), and the incidence of adverse reactions of group B was significantly lower than that of group A (χ²=3.53, P<0.05). The recurrence rate of group C was significantly lower than that of group A and group B (χ²=6.13, P<0.05), and the recurrence rate of group B was significantly lower than that of group A (χ²=5.00, P<0.05). Conclusion Vestibular rehabilitation training combined with betahistine mesylate had obvious effect for treating elderly patients with BPPV, which could effectively shorten treatment period and decrease recurrence rate.

Huanan Guofang Yixue Zazhi published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C18H23N3O4S, Category: pyridine-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Liao, Jun published the artcileEfficacy of vestibular rehabilitation training combined with medication in treatment of vestibular neuritis, Computed Properties of 54856-23-4, the publication is Sichuan Yixue (2017), 38(3), 332-334, database is CAplus.

Objective: To observe and evaluate the clin. effect of vestibular rehabilitation training combined with drug therapy in the treatment of vestibular neuritis. Methods: 30 cases of vestibular neuritis diagnosed during hospital stay between Sept. 2014 and Sept. 2015 in our department were included. 15 patients in exptl. group received vestibular rehabilitation training combined with drug therapy and 15 patients in control group only received drug therapy. Dizziness Handicap Inventory (DHI) scores on admission and 4 wk after onset of exptl. group and control group were compared. Results: Difference of DHI scores on admission between the two groups was not statistically significant (P>0.05). Both in two groups, differences of DHI scores before and after treatment were statistically significant (P<0.05). After 1 mo of treatment, comparing the differences of DHI scores in the two groups, the difference being statistically significant (P<0.05). Conclusion: Vestibular rehabilitation training combined with drug therapy can improve the prognosis of patients with vestibular neuritis.

Sichuan Yixue published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Computed Properties of 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Duan, Jingli published the artcileBioequivalence of domestic and imported betahistine mesylate tablets in healthy volunteers, Product Details of C10H20N2O6S2, the publication is Zhongguo Linchuang Yaolixue Zazhi (2003), 19(1), 42-45, database is CAplus.

The objective of this study was to determine the bioequivalence of domestic and imported betahistine mesylate in 20 healthy volunteers. A single dose of 24 mg domestic and imported betahistine mesylate tablets was given according to an open randomized 2-way crossover design. Plasma concentration of the main metabolite of betahistine, pyridine-2-ethanoic acid, was determined by HPLC/MS/MS method. The pharmacokinetics parameters of the two products were as follow: C_max 308.6 ± 208.8 mg L^-1 and 339.4 ± 213.4 mg L^-1; t_max 1.13 ± 0.66 h and 0.98 ± 0.47 h; AUC_0-t 1168.5 ± 794.9 mg L^-1 and 1129.3 ± 725.2 mg L^-1; AUC_0-∞ were 1213.2 ± 819.2 mg L^-1 and 1178.9 ± 752.5 mg L^-1, resp. The relative bioavailability of domestic product was (106.3 ± 29.1%). The results demonstrated that the two formations were bioequivalent by anal. of variance, two-one side test and 90% internal confidence.

Zhongguo Linchuang Yaolixue Zazhi published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Product Details of C10H20N2O6S2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Mikami, Eiichi published the artcileRapid determination of drugs in pharmaceutical preparations by liquid chromatography. (III). Determination of todralazine hydrochloride, trimetoquinol hydrochloride, nicardipine hydrochloride, sulpiride, furosemide and betahistine mesilate in pharmaceutical preparations, Formula: C10H20N2O6S2, the publication is Iyakuhin Kenkyu (1992), 23(6), 896-901, database is CAplus.

Liquid chromatog. methods using UV detection are described for determination of the title drugs in pharmaceutical preparations Stationary phase was Wakosil 5C18. Internal standards were p-hydroxybenzoic acid (for todralazine hydrochloride and sulpiride), Me p-aminobenzoate (for trimetoquinol hydrochloride and betahistidine mesilate), Pr p-hydroxybenzoate (for nicardipine hydrochloride), and Pr p-aminobenzoate (for furosemide). These rapid methods are useful for anal. for com. pharmaceutical preparations

Iyakuhin Kenkyu published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Formula: C10H20N2O6S2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Chen, Hong-hua published the artcileEfficacy of manual reduction combined with betahistine mesylate in treatment of benign paroxysmal positional vertigo, SDS of cas: 54856-23-4, the publication is Xiandai Zhenduan Yu Zhiliao (2017), 28(7), 1235-1236, database is CAplus.

To explore the efficacy of manual reduction combined with drugs in the treatment of 60 cases of benign paroxysmal positional vertigo. Patients who were diagnosed with benign paroxysmal positional vertigo in our hospital from Feb. 2013 to Jan. 2015 were collected and randomly divided into a study group and a control group. The basic treatment of the two groups was manual reduction, and the study group was treated with betahistine mesylate tablets. The therapeutic effects of the two groups were compared for benign paroxysmal positional vertigo. The two groups were scored by the Vertigo Disorder Rating Scale before and after treatment. The therapeutic effects of the study group and the control group for benign paroxysmal positional vertigo were 100% and 66.7%, resp., and there was a difference (P < 0.05). The study group and the control group had no difference in the scores of the Vertigo Disorder Rating Scale before treatment (P > 0.05). There was a difference in the scores of the vertigo disorder rating scale between the study group and the control group after treatment (P < 0.05). This article believes that manual reduction combined with drugs has a definite effect in the treatment of benign paroxysmal positional vertigo and can significantly improve the symptoms of patients.

Xiandai Zhenduan Yu Zhiliao published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, SDS of cas: 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Yang, Wan-jing published the artcileEffect of vestibular rehabilitation training combined with betahistine mesylate on elderly patients with benign paroxysmal positional vertigo, Category: pyridine-derivatives, the publication is Huanan Guofang Yixue Zazhi (2016), 30(1), 71-72, database is CAplus.

Objective To investigate the effect of vestibular rehabilitation training combined with betahistine mesylate on elderly patients with benign positional paroxysmal vertigo (BPPV). Methods 120 elderly patients with BPPV were randomized into three groups: group A was treated with vestibular rehabilitation training, group B was treated by oral administration of betahistine mesylate, and group C was treated by vestibular rehabilitation training combined with oral administration of betahistine mesylate. Results The total effective rate of group C was significantly higher than that of group A and group B (χ²=11.61, P<0.05), and the total effective rate of group B was significantly higher than that of group A (χ²=8.90, P<0.05). The incidence of adverse reactions of group C was significantly lower than that of group A and group B (χ²=4.50, P<0.05), and the incidence of adverse reactions of group B was significantly lower than that of group A (χ²=3.53, P<0.05). The recurrence rate of group C was significantly lower than that of group A and group B (χ²=6.13, P<0.05), and the recurrence rate of group B was significantly lower than that of group A (χ²=5.00, P<0.05). Conclusion Vestibular rehabilitation training combined with betahistine mesylate had obvious effect for treating elderly patients with BPPV, which could effectively shorten treatment period and decrease recurrence rate.

Huanan Guofang Yixue Zazhi published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C18H23N3O4S, Category: pyridine-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Liao, Jun published the artcileEfficacy of vestibular rehabilitation training combined with medication in treatment of vestibular neuritis, Computed Properties of 54856-23-4, the publication is Sichuan Yixue (2017), 38(3), 332-334, database is CAplus.

Objective: To observe and evaluate the clin. effect of vestibular rehabilitation training combined with drug therapy in the treatment of vestibular neuritis. Methods: 30 cases of vestibular neuritis diagnosed during hospital stay between Sept. 2014 and Sept. 2015 in our department were included. 15 patients in exptl. group received vestibular rehabilitation training combined with drug therapy and 15 patients in control group only received drug therapy. Dizziness Handicap Inventory (DHI) scores on admission and 4 wk after onset of exptl. group and control group were compared. Results: Difference of DHI scores on admission between the two groups was not statistically significant (P>0.05). Both in two groups, differences of DHI scores before and after treatment were statistically significant (P<0.05). After 1 mo of treatment, comparing the differences of DHI scores in the two groups, the difference being statistically significant (P<0.05). Conclusion: Vestibular rehabilitation training combined with drug therapy can improve the prognosis of patients with vestibular neuritis.

Sichuan Yixue published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Computed Properties of 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Duan, Jingli published the artcileBioequivalence of domestic and imported betahistine mesylate tablets in healthy volunteers, Product Details of C10H20N2O6S2, the publication is Zhongguo Linchuang Yaolixue Zazhi (2003), 19(1), 42-45, database is CAplus.

The objective of this study was to determine the bioequivalence of domestic and imported betahistine mesylate in 20 healthy volunteers. A single dose of 24 mg domestic and imported betahistine mesylate tablets was given according to an open randomized 2-way crossover design. Plasma concentration of the main metabolite of betahistine, pyridine-2-ethanoic acid, was determined by HPLC/MS/MS method. The pharmacokinetics parameters of the two products were as follow: C_max 308.6 ± 208.8 mg L^-1 and 339.4 ± 213.4 mg L^-1; t_max 1.13 ± 0.66 h and 0.98 ± 0.47 h; AUC_0-t 1168.5 ± 794.9 mg L^-1 and 1129.3 ± 725.2 mg L^-1; AUC_0-∞ were 1213.2 ± 819.2 mg L^-1 and 1178.9 ± 752.5 mg L^-1, resp. The relative bioavailability of domestic product was (106.3 ± 29.1%). The results demonstrated that the two formations were bioequivalent by anal. of variance, two-one side test and 90% internal confidence.

Zhongguo Linchuang Yaolixue Zazhi published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Product Details of C10H20N2O6S2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Mikami, Eiichi published the artcileRapid determination of drugs in pharmaceutical preparations by liquid chromatography. (III). Determination of todralazine hydrochloride, trimetoquinol hydrochloride, nicardipine hydrochloride, sulpiride, furosemide and betahistine mesilate in pharmaceutical preparations, Formula: C10H20N2O6S2, the publication is Iyakuhin Kenkyu (1992), 23(6), 896-901, database is CAplus.

Liquid chromatog. methods using UV detection are described for determination of the title drugs in pharmaceutical preparations Stationary phase was Wakosil 5C18. Internal standards were p-hydroxybenzoic acid (for todralazine hydrochloride and sulpiride), Me p-aminobenzoate (for trimetoquinol hydrochloride and betahistidine mesilate), Pr p-hydroxybenzoate (for nicardipine hydrochloride), and Pr p-aminobenzoate (for furosemide). These rapid methods are useful for anal. for com. pharmaceutical preparations

Iyakuhin Kenkyu published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, Formula: C10H20N2O6S2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem